ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Weak Structure, Deficiencies, Cited In Dana-Farber Reviews

November 3, 1995

In Brief: Debbie Mayer Elected ONS President; Cullen, Other NCI Staff Honored By Surgeon General

May 15, 1987

DCT T Consider Reissuing RFA For Surgical Oncology

March 4, 1983

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

May 30, 2014

New CCP Lineup remains Unclear; 11 Bases OK’d

April 5, 1991

Patient Care Emerges as Major Concern Following Sequestration Cuts to Medicare

April 5, 2013